The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
For World AIDS Day, read about stigma, criminalization and more >>
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

March 24, 2014

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 from this large randomised open label study with over 1800 treatment naive participants. [1]

The study was designed based on a hypothesis of equivalence for the three groups, with 90% power to define any pair-wise comparison.

Equivalence was defined based on cumulative incidence of events at 96 weeks if the 97.5% CI for results fell within +/-10% margin. Superiority required the upper limit of the 97.5% CI to be greater than 10% and the lower limit greater than zero. All three study groups used

View Full Article

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Visit HIV i-Base's website to find out more about their activities, publications and services.
See Also
More on HIV Medications
More News and Research on Atazanavir (Reyataz)

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: